AU2022420983A1 - Bifunctional sulphonamide compounds - Google Patents

Bifunctional sulphonamide compounds Download PDF

Info

Publication number
AU2022420983A1
AU2022420983A1 AU2022420983A AU2022420983A AU2022420983A1 AU 2022420983 A1 AU2022420983 A1 AU 2022420983A1 AU 2022420983 A AU2022420983 A AU 2022420983A AU 2022420983 A AU2022420983 A AU 2022420983A AU 2022420983 A1 AU2022420983 A1 AU 2022420983A1
Authority
AU
Australia
Prior art keywords
optionally substituted
compound
alkyl
mmol
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022420983A
Other languages
English (en)
Inventor
Martin Brzozowski
Christopher Gardner
Jean-Marc Daniel GARNIER
Wilhelmus Johannes Antonius KERSTEN
Guillaume Laurent Lessene
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anaxis Pharma Pty Ltd
Original Assignee
Anaxis Pharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021904204A external-priority patent/AU2021904204A0/en
Application filed by Anaxis Pharma Pty Ltd filed Critical Anaxis Pharma Pty Ltd
Publication of AU2022420983A1 publication Critical patent/AU2022420983A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2022420983A 2021-12-22 2022-12-22 Bifunctional sulphonamide compounds Pending AU2022420983A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021904204A AU2021904204A0 (en) 2021-12-22 Bifunctional sulphonamide compounds
AU2021904204 2021-12-22
PCT/AU2022/051575 WO2023115149A1 (en) 2021-12-22 2022-12-22 Bifunctional sulphonamide compounds

Publications (1)

Publication Number Publication Date
AU2022420983A1 true AU2022420983A1 (en) 2024-07-04

Family

ID=86900865

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022420983A Pending AU2022420983A1 (en) 2021-12-22 2022-12-22 Bifunctional sulphonamide compounds

Country Status (9)

Country Link
US (1) US20250074891A1 (https=)
EP (1) EP4452966A4 (https=)
JP (1) JP2025501765A (https=)
KR (1) KR20240151737A (https=)
CN (1) CN119013268A (https=)
AU (1) AU2022420983A1 (https=)
CA (1) CA3241593A1 (https=)
MX (1) MX2024007883A (https=)
WO (1) WO2023115149A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025096550A1 (en) * 2023-10-31 2025-05-08 Twine Therapeutics, Inc. Methods of treating cardiomyopathy
WO2025155642A1 (en) * 2024-01-21 2025-07-24 The Regents Of The University Of California Dcaf16-based covalent handle for the rational design of monovalent degraders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2948544A1 (en) * 2014-05-15 2015-11-19 Catalyst Therapeutics Pty Ltd Methods for inhibiting necroptosis
CA2976121A1 (en) * 2015-02-10 2016-08-18 Catalyst Therapeutics Pty Ltd Inhibitors of necroptosis
WO2018192416A1 (en) * 2017-04-17 2018-10-25 National Institute Of Biological Sciences, Beijing Treating Male Senescence
CN114521196A (zh) * 2019-09-16 2022-05-20 诺华股份有限公司 双官能团降解剂及其使用方法
DK4168401T3 (da) * 2020-06-19 2026-04-13 Anaxis Pharma Pty Ltd Sulfonamidforbindelser

Also Published As

Publication number Publication date
US20250074891A1 (en) 2025-03-06
WO2023115149A1 (en) 2023-06-29
CA3241593A1 (en) 2023-06-29
CN119013268A (zh) 2024-11-22
JP2025501765A (ja) 2025-01-23
EP4452966A4 (en) 2025-12-17
EP4452966A1 (en) 2024-10-30
KR20240151737A (ko) 2024-10-18
MX2024007883A (es) 2024-09-23

Similar Documents

Publication Publication Date Title
KR102073797B1 (ko) 단백질 키나제 저해제로서의 아미노피리다지논 화합물
CA3082212C (en) Bruton's tyrosine kinase inhibitors
RU2517194C2 (ru) Пирролопиридины как ингибиторы киназы
EP4168401B1 (en) Sulphonamide compounds
CN116669727A (zh) 作为lpa受体拮抗剂的三唑-吡啶基取代的氮杂环己基乙酸化合物
AU2013216721A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
JP2023538304A (ja) 化合物、組成物及び方法
WO2018175512A1 (en) Bruton's tyrosine kinase inhibitors
AU2022422212A1 (en) Bifunctional arylsulphonamide compounds
AU2022420983A1 (en) Bifunctional sulphonamide compounds
CN116981458A (zh) 具有四氢吲哚-1-甲酰胺作为bcl-2抑制剂的化合物
AU2021290652A1 (en) Amido compounds
EP4452977A1 (en) Arylsulphonamide compounds
CN121085992A (zh) 信号转导及转录激活蛋白6选择性降解剂化合物
BR112019019588B1 (pt) Composto e composição farmacêutica
HK1212975A1 (zh) 作为布鲁顿氏酪氨酸激酶抑制剂的噻唑衍生物

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ BRZOZOWSKI, MARTIN; GARNIER, JEAN-MARC DANIEL; GARDNER, CHRISTOPHER; LESSENE, GUILLAUME LAURENT AND KERSTEN, WILHELMUS JOHANNES ANTONIUS